

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7231600

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECURITY INTEREST	
CONVEYING PARTY DATA		
Name		Execution Date
UROGEN PHARMA LTD.		03/16/2022
RECEIVING PARTY DATA		
Name:	BIOPHARMA CREDIT PLC	
Street Address:	C/O BEAUFORT HOUSE, 51 NEW NORTH ROAD	
City:	EXETER EX4 4EP	
State/Country:	UNITED KINGDOM	
PROPERTY NUMBERS Total: 42		
Property Type	Number	
Patent Number:	9040074	
Patent Number:	10039832	
Patent Number:	9950069	
Patent Number:	8361490	
Patent Number:	9011411	
Patent Number:	8936566	
Patent Number:	9884028	
Patent Number:	9173935	
Patent Number:	9173936	
Patent Number:	9180183	
Patent Number:	9050319	
Patent Number:	9540407	
Patent Number:	9066940	
Patent Number:	9107919	
Patent Number:	10471150	
Patent Number:	10994109	
Patent Number:	9801854	
Patent Number:	10758482	
Patent Number:	10144779	
Patent Number:	10479833	
Patent Number:	11267889	

PATENT

Property Type	Number
Application Number:	16518511
Application Number:	17566882
Application Number:	16593297
Application Number:	17006926
Application Number:	17546204
Application Number:	63165744
Application Number:	17582839
Application Number:	62168391
Application Number:	62182363
Application Number:	62190653
Application Number:	62257202
Application Number:	62280263
Application Number:	62292500
Application Number:	62294558
Application Number:	62323226
Application Number:	16572216
Application Number:	16435175
Application Number:	62431279
Application Number:	62570451
Application Number:	62582814
Application Number:	62586605

CORRESPONDENCE DATA

Fax Number: (202)887-4288

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2028874000

Email: mbeyene@akingump.com, DC_IPDocketing@AKINGUMP.com

Correspondent Name: MUSSIE B BEYENE

Address Line 1: 2001 K STREET N.W.

Address Line 4: WASHINGTON DC, D.C. 20006

ATTORNEY DOCKET NUMBER:	687747.0065
NAME OF SUBMITTER:	MUSSIE B BEYENE
SIGNATURE:	/Mussie B Beyene/
DATE SIGNED:	03/18/2022

Total Attachments: 20

source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page1.tif

source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page2.tif

source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page3.tif

source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page4.tif

source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page5.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page6.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page7.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page8.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page9.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page10.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page11.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page12.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page13.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page14.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page15.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page16.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page17.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page18.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page19.tif
source=Pharmakon - UroGen -- Patent Security Agreement [Executed] 4869-8009-9349, 1#page20.tif

PATENT SECURITY AGREEMENT

THIS PATENT SECURITY AGREEMENT, dated as of March 16, 2022, is made by UROGEN PHARMA LTD. ("Grantor"), in favor of BIOPHARMA CREDIT PLC (together with its successors and permitted assigns, the "Collateral Agent") on behalf of Lenders and the other Secured Parties (as defined in the Loan Agreement referred to below).

W I T N E S S E T H:

WHEREAS, pursuant to the Loan Agreement, dated as of March 7, 2022 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), by and among UROGEN PHARMA, INC., a Delaware corporation ("Borrower"), UROGEN PHARMA LTD., a company incorporated in Israel with company registration number 513537621 (as "Parent" and a Credit Party), the other parties thereto from time to time, as additional Credit Parties, BIOPHARMA CREDIT PLC, as Collateral Agent, BPCR LIMITED PARTNERSHIP, (as a "Lender") and BIOPHARMA CREDIT INVESTMENTS V (MASTER) LP, a Cayman Islands exempted limited partnership acting by its general partner, BioPharma Credit Investments V GP LLC (as a "Lender"), each Lender has agreed to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, Grantor has agreed, pursuant to a Guaranty and Security Agreement dated as of March 16, 2022 in favor of the Collateral Agent for the benefit of Lenders and the other Secured Parties (as such agreement may be amended, amended and restated, supplemented or otherwise modified from time to time, the "Guaranty and Security Agreement"), to guarantee the Obligations (as defined in the Loan Agreement) of Borrower; and

WHEREAS, Grantor is party to the Guaranty and Security Agreement pursuant to which Grantor is required to execute and deliver this Patent Security Agreement;

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:

Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.

Section 2. Grant of Security Interest in Patent Collateral. Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, hereby mortgages, pledges and hypothecates to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, and grants to the Collateral Agent, for the benefit of Lenders and the other Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of Grantor, in each case, solely to the extent constituting Collateral (and excluding any Excluded Property) (the "Patent Collateral"):

(a) all of its Patents and all IP License and IP Ancillary Rights providing for the grant by or to Grantor of any right under any Patent, including, without limitation, those referred to on Schedule 1 hereto;

(b) all reissues, reexaminations, continuations, continuations-in-part, divisionals, substitutes, renewals and any patent term extension or adjustment (including any supplementary protection certificate) of the foregoing, and any patent issued with respect to any of the foregoing, and any confirmation patent or registration patent or patent of addition based on any such patent; and

(c) all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.

Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Patent Security Agreement is granted in conjunction with the security interest granted to the Collateral Agent for the benefit of Lenders and the other Secured Parties, pursuant to the Guaranty and Security Agreement and Grantor hereby acknowledges and agrees that the obligations, rights and remedies of Grantor and of the Collateral Agent on behalf of Lenders and the other Secured Parties with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.

Section 4. Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other reasonably necessary actions in connection with its Patents and IP Licenses subject to a security interest hereunder.

Section 5. Counterparts. This Patent Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart. Delivery of an executed signature page of this Patent Security Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof.

Section 6. Governing Law. THIS PATENT SECURITY AGREEMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO ANY PRINCIPLES OF CONFLICTS OF LAW THAT COULD REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION, PROVIDED, HOWEVER, THAT IF THE LAWS OF ANY JURISDICTION OTHER THAN NEW YORK SHALL GOVERN IN REGARD TO THE VALIDITY, PERFECTION OR EFFECT OF PERFECTION OF ANY LIEN OR IN REGARD TO PROCEDURAL MATTERS AFFECTING ENFORCEMENT OF ANY LIENS IN PATENT COLLATERAL, SUCH LAWS OF SUCH OTHER JURISDICTIONS SHALL APPLY TO THAT EXTENT.

THE TERMS OF SECTION 10 OF THE LOAN AGREEMENT ARE INCORPORATED HEREIN BY REFERENCE, *MUTATIS MUTANDIS*, AS IF SET FORTH IN FULL HEREIN AND THE PARTIES HERETO AGREE TO SUCH TERMS AND TO BE BOUND BY SUCH TERMS.

Section 7. Termination. Upon the absolute, unconditional and irrevocable payment in full of the Secured Obligations in accordance with the provisions of the Loan Agreement and the expiration or termination of the Term Loan Commitments, the security interest in the Patent Collateral granted hereby shall automatically terminate, without delivery of any instrument or performance of any act by any party, and all rights to the Patent Collateral shall automatically revert to Grantors or any other Person entitled thereto. At such time, the Collateral Agent authorizes the filing by such Grantor of an appropriate termination hereof.

Section 8. Intercreditor Agreement. Notwithstanding anything herein to the contrary, the security interest granted pursuant to this Patent Security Agreement, the terms of this Patent Security Agreement and the exercise of any right or remedy hereunder are subject to the provisions of the Intercreditor Agreement, dated as of March 16, 2022, by and between the Collateral Agent, RTW Investments ICAV (for and on behalf of RTW Fund 2) and acknowledged and agreed to by Grantor and Borrower (as may be amended, restated, amended and restated, supplemented or otherwise modified from time to time).

IN WITNESS WHEREOF, Grantor has caused this Patent Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,
UROGEN PHARMA LTD.,
as Grantor

By: Molly Henderson
Name: Molly Henderson
Title: Chief Financial Officer

Signature Page to Patent Security Agreement


PATENT
REEL: 059302 FRAME: 0506

ACCEPTED AND AGREED
as of the date first above written:

BIOPHARMA CREDIT PLC,
as Collateral Agent

By: Pharmakon Advisors, LP,
its Investment Manager

By: Pharmakon Management I, LLC,
its General Partner

By: 
Name: Pedro Gonzalez de Cosio
Title: Managing Member

Signature Page to Patent Security Agreement

SCHEDULE 1
TO
PATENT SECURITY AGREEMENT

Patent Registrations/Applications and IP Licenses

PATENTS

Name of Entity	Jurisdiction	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Grant Date	Status
Urogen Pharma Ltd	United States	13/553,198	July 19, 2012	2013-0046275	February 21, 2013	9,040,074	May 26, 2015	Granted
Urogen Pharma Ltd	United States	14/720,676	May 22, 2015	2015-0366974	December 24, 2015	10,039,832	August 7, 2018	Granted
Urogen Pharma Ltd	United States	15/366,256	December 1, 2016	2017-0112935	April 27, 2017	9,950,069	April 24, 2018	Granted
Urogen Pharma Ltd	United States	16/518,511	July 22, 2019	2020-0114008	April 16, 2020			Pending as of February 8, 2022
Urogen Pharma Ltd	United States	17/566,882	December 31, 2021					Not published as of Feb. 8, 2022
Urogen Pharma Ltd	Germany	201160059335	January 20, 2011	602011059335				Granted
Urogen Pharma Ltd	Denmark	20110706027	January 20, 2011			2,525,777	July 1, 2019	Granted
Urogen Pharma Ltd	Europe	20110706027	January 20, 2011	2525777	October 26, 2012	2,525,777	May 29, 2019	Granted

Name of Entity	Jurisdiction	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Grant Date	Status
Urogen Pharma Ltd	Spain	20110706027	January 20, 2011			2,732,150	Nov. 20, 2019	Granted
Urogen Pharma Ltd	Israel	20110221040	January 20, 2011	221040	November 30, 2017	221040	March 29, 2018	Granted
Urogen Pharma Ltd	United States	10/941,942	September 16, 2004	2006-0057208	March 16, 2006	8,361,490	January 29, 2013	Granted
Urogen Pharma Ltd	United States	13/726,162	December 23, 2012	2013-0110030	May 2, 2013	9,011,411	April 21, 2015	Granted
Urogen Pharma Ltd	United States	13/726,165	December 23, 2012	2013-0110031	May 2, 2013	8,936,566	January 20, 2015	Granted
UroGen Pharma Ltd	United States	14/683,901	April 10, 2015	2015-0209300	July 30, 2015	9,884,028	February 6, 2018	Granted
Urogen Pharma Ltd	United States	13/097,838	April 29, 2011	2012-0009247	January 12, 2012	9,173,935	November 3, 2015	Granted
Urogen Pharma Ltd	United States	13/772,235	February 20, 2013	2013-0267481	October 10, 2013	9,173,936	November 3, 2015	Granted
Urogen Pharma Ltd	United States	13/772,253	February 20, 2013	2013-0266635	October 10, 2013	9,180,183	November 10, 2015	Granted
Urogen Pharma Ltd	United States	13/775,924	February 25, 2013	2013-0273144	October 17, 2013	9,050,319	June 9, 2015	Granted
Urogen Pharma Ltd	United States	14/869,677	September 29, 2015	2016-0090395	March 31, 2016	9,540,407	January 10, 2017	Granted
Urogen Pharma Ltd	Australia	20110247358	April 29, 2011	2011247358	November 3, 2011	2011247358	October 30, 2014	Granted

Name of Entity	Jurisdiction	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Grant Date	Status
Urogen Pharma Ltd	Canada	20112797315	April 29, 2011	2797315	October 24, 2012	2797315	September 11, 2018	Granted
Urogen Pharma Ltd	China	201180032644	April 29, 2011	103221067	July 24, 2013	103221067	January 6, 2016	Granted
Urogen Pharma Ltd	Europe	20110720031	April 29, 2011	2563404	March 6, 2013	2563404	September 21, 2016	Granted
Urogen Pharma Ltd	Europe	20130766473	September 24, 2013	2903987	August 12, 2015	2903987	September 20, 2017	Granted
Urogen Pharma Ltd	Hong Kong	20130109651	August 19, 2013	1182322	November 29, 2013			Pending as of March 9, 2022
Urogen Pharma Ltd	Israel	20130237221	September 24, 2013	237221	September 28, 2017	237221	January 31, 2018	Granted
Urogen Pharma Ltd	Japan	20130506541	April 29, 2011	2013525390	June 20, 2013	6026405	November 1, 2016	Granted
Urogen Pharma Ltd	New Zealand	20110603155	April 29, 2011	603155	June 27, 2014	603155	October 31, 2014	Granted
Urogen Pharma Ltd	United States	13/147,194	September 14, 2011	2011-0319442	December 29, 2011	9,066,940	June 30, 2015	Granted
Urogen Pharma Ltd	United States	13/775,906	February 25, 2013	2013-0237561	September 12, 2013	9,107,919	August 18, 2015	Granted
Urogen Pharma Ltd	Australia	20100211216	February 5, 2010	2010211216	August 12, 2010	2010211216	August 28, 2014	Granted
Urogen Pharma Ltd	Canada	20102741052	February 5, 2010	2741052	April 18, 2011	2741052	May 7, 2019	Granted

Name of Entity	Jurisdiction	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Grant Date	Status
Urogen Pharma Ltd	China	201080006838	February 5, 2010	102307569	January 4, 2012	102307569	December 10, 2014	Granted
Urogen Pharma Ltd	Germany	201060012172	February 5, 2010	602010012172				Granted
Urogen Pharma Ltd	Germany	201060041398	February 5, 2010	602010041398				Granted
Urogen Pharma Ltd	Denmark	20100703023	February 5, 2010			2393474	January 13, 2014	Granted
Urogen Pharma Ltd	Europe	20100703023	February 5, 2010	2393474	December 14, 2011	2393474	December 4, 2013	Granted
Urogen Pharma Ltd	Europe	20130001958	February 5, 2010	2641590	September 25, 2013	2641590	April 5, 2017	Granted
Urogen Pharma Ltd	Spain	20100703023	February 5, 2010			2450420	March 24, 2014	Granted
Urogen Pharma Ltd	Israel	20100212734	February 5, 2010	212734	July 31, 2019	212734	Nov. 28, 2019	Granted
Urogen Pharma Ltd	Japan	20110548612	February 5, 2010	2012516865	July 26, 2012	5702734	April 15, 2015	Granted
Urogen Pharma Ltd	Japan	20140208858	October 10, 2014	2015042655	March 5, 2015	5923581	May 24, 2016	Granted
Urogen Pharma Ltd	Mexico	20110007702	February 5, 2010	2011007702	August 8, 2011	325828	December 1, 2014	Granted
Urogen Pharma Ltd	San Marino	20140000040T	April 2, 2014			T201400040	May 7, 2014	Granted

Name of Entity	Jurisdiction	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Grant Date	Status
Urogen Pharma Ltd	United States	16/593,297	October 4, 2019	2020-0276183	September 3, 2020			Pending as of February 8, 2022
Urogen Pharma Ltd	China	201580004299	January 8, 2015	106456630	February 22, 2017			Pending as of February 14, 2022
Urogen Pharma Ltd	Germany	201560072354	January 8, 2015	602015072354				Granted
Urogen Pharma Ltd	Europe	20150702368	January 8, 2015	3091978	November 16, 2016	3091978	August 18, 2021	Granted
Urogen Pharma Ltd	Spain	20150702368	January 8, 2015			2891148	January 26, 2022	Granted
Urogen Pharma Ltd	Japan	20160563246	January 8, 2015	2017502084	January 19, 2017	6495332	April 3, 2019	Granted
Urogen Pharma Ltd	Europe	20120814463	July 19, 2012	2734557	May 28, 2014			Pending as of Feb. 14, 2022
Urogen Pharma Ltd	United States	14/054,731	October 15, 2013	2014-0105884	April 17, 2014	10,471,150	November 12, 2019	Granted
Urogen Pharma Ltd	United States	15/322,044	December 23, 2016	2017-0136222	May 18, 2017	10,994,109	May 4, 2021	Granted
Urogen Pharma Ltd	United States	14/600,354	January 20, 2015	Not published before grant		9,801,854	October 31, 2017	Granted
Urogen Pharma Ltd	United States	16/297,839	March 11, 2019	2019-0201334	July 4, 2019	10,758,482	September 1, 2020	Granted

Name of Entity	Jurisdiction	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Grant Date	Status
Urogen Pharma Ltd	United States	17/006,926	August 31, 2020	2020-0397695	December 24, 2020			Pending as of February 14, 2022
Urogen Pharma Ltd	Europe	20170865040	October 25, 2017	3532505	September 4, 2019			Pending as of Feb. 14, 2022
Urogen Pharma Ltd	Europe	20200162473	March 11, 2020	3708167	September 16, 2020			Pending as of Feb. 14, 2022
Urogen Pharma Ltd	Japan	20190542827	October 25, 2017	JP2019535810	December 12, 2019			Pending as of Feb. 14, 2022
Urogen Pharma Ltd	WIPO	PCT/IB2021/061499	December 9, 2021					Not published as of Feb. 8, 2022
Urogen Pharma Ltd	United States	17/546,204	December 9, 2021					Not published as of Feb. 8, 2022
Urogen Pharma Ltd	United States	63/165,744	March 25, 2021					Pending as of Feb. 14, 2022
Urogen Pharma Ltd	Germany	201260050686	July 19, 2012	602012050686				Granted
Urogen Pharma Ltd	Europe	20120762404	July 19, 2012	2734187	May 28, 2014	2734187	September 5, 2018	Granted
Urogen Pharma Ltd	Israel	20120230530	July 19, 2012	230530	April 29, 2021	230530	August 31, 2021	Granted
Urogen Pharma Ltd	Germany	201360070731	April 8, 2013	602013070731				Granted

Name of Entity	Jurisdiction	Application Number	Filing Date	Publication Number	Publication Date	Patent Number	Grant Date	Status
Urogen Pharma Ltd	Denmark	20130775035	April 8, 2013			2836200	September 21, 2020	Granted
Urogen Pharma Ltd	Europe	20130775035	April 8, 2013	2836200	February 18, 2015	2836200	July 15, 2020	Granted
Urogen Pharma Ltd	Spain	20130775035	April 8, 2013			2821098	April 23, 2021	Granted
Urogen Pharma Ltd	Israel	20130236000	April 8, 2013	236000	January 29, 2015	236000		Allowed and Published for Opposition Purposes
Urogen Pharma Ltd	Russia	20140144727	April 8, 2013	2014144727	May 27, 2016	2635466	November 13, 2017	Granted
Urogen Pharma Ltd	Mexico	MX/a/2010/008697	February 6, 2009	2010008697	December 7, 2010	303980	October 3, 2012	Granted

Exclusively Licensed Patents

Name of Entity	Owner(s) (Licensor(s))	Title	Jurisdiction	Application No.	Filing Date	Patent No. (Grant Date)	Status
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	United States	15/166,305	05/27/2016	10,144,779 (12/04/2018)	Granted

Name of Entity	Owner(s) (Licensor(s))	Title	Jurisdiction	Application No.	Filing Date	Patent No. (Grant Date)	Status
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	16/165,833	10/19/2018	10,479,833 (11/19/2019)	Granted
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	16/858,195	04/24/2020	11,267,889 (03/08/2022)	To be granted
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	17/582,839	01/24/2022		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Australia	2019204586	06/28/2019	2019204586 (09/09/2021)	Granted
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Australia	2021211991	08/03/2021		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Canada	2986765	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	China	20168004288 7.8	05/27/2016	107849144 (09/17/2021)	Granted

Name of Entity	Owner(s) (Licensor(s))	Title	Jurisdiction	Application No.	Filing Date	Patent No. (Grant Date)	Status
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	China	202111057251X	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Eurasia	201792665	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Eurasia	202192665	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Europe	16728509.7	05/27/2016	3303394 (04/08/2020)	Granted In force in ES, PT, AT, IE, DE, GB, IT, MT
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Europe	20168222.6	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Hong Kong	18112539.3	05/27/2016	HK 1253250 (01/22/2021)	Granted
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Hong Kong	42021030164.4	04/29/2021		Pending

Name of Entity	Owner(s) (Licensor(s))	Title	Jurisdiction	Application No.	Filing Date	Patent No. (Grant Date)	Status
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Israel	255468	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	India	201717044440	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Japan	2017-561965	05/27/2016	6900323 (06/18/2021)	Granted
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Japan	2021-100134	06/16/2021		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Korea	10-2017-7037545	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Macau	J/005650	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Mexico	MX/a/2017/015046	05/27/2016		Pending

Name of Entity	Owner(s) (Licensor(s))	Title	Jurisdiction	Application No.	Filing Date	Patent No. (Grant Date)	Status
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Singapore	11201709182 U	05/27/2016	11201709182 U (11/08/2021)	Granted
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Singapore	10201913500 T	12/27/2019		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Argentina	20160101558	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Brazil	11201702556 4-2	05/27/2016	11201702556 4 (12/21/2021)	Granted
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Brazil	12202100051 2-5	01/12/2021		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Chile	201703023	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTLA-4 Antibodies and Methods of Use Thereof	Colombia	NC2017/0013 398	05/27/2016	35598 (09/16/2019)	Granted

Name of Entity	Owner(s) (Licensor(s))	Title	Jurisdiction	Application No.	Filing Date	Patent No. (Grant Date)	Status
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Peru	2485-2017	05/27/2016		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Turkey	2020/10411	05/27/2016	2020 10411 (07/21/2020)	Granted
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	Australia	2016271591	05/27/2016		Abandoned
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	WIPO	PCT/US2016/034508	05/27/2016		Nationalized
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	62/168,391	05/29/2015		Expired
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	62/182,363	06/19/2015		Expired
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	62/190,653	07/09/2015		Expired

Name of Entity	Owner(s) (Licensor(s))	Title	Jurisdiction	Application No.	Filing Date	Patent No. (Grant Date)	Status
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	62/257,202	11/18/2015		Expired
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	62/280,263	01/19/2016		Expired
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	62/292,500	02/08/2016		Expired
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	62/294,558	02/12/2016		Expired
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	62/323,226	04/15/2016		Expired
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	Anti-CTL A-4 Antibodies and Methods of Use Thereof	United States	16/572,216	09/16/2019		Abandoned
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIES AND METHODS OF USE THEREOF	United States	16/435,175	12/07/2017		Pending

Name of Entity	Owner(s) (Licensor(s))	Title	Jurisdiction	Application No.	Filing Date	Patent No. (Grant Date)	Status
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	Argentina	P20170103466	12/12/2017		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	Australia	2017373945	12/07/2017		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	Brazil	BR 11 2019 011582 0	12/07/2017		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	Canada	3046082	12/07/2017		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	Chile	CL 201901517	12/07/2017		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	China	20178008567 2.9	12/07/2017		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	Colombia	NC2019/0006 485	12/07/2017		Pending

Name of Entity	Owner(s) (Licensor(s))	Title	Jurisdiction	Application No.	Filing Date	Patent No. (Grant Date)	Status
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	Europe	17818020.4	12/07/2017		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	Hong Kong	62020004841.6	12/07/2017		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	Japan	2019-530429	12/07/2017		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	Korea	10-2019-7018683	12/07/2017		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	Peru	PE 1209-2019	12/07/2017		Pending
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	WIPO	PCT/US17/65014	12/7/2017		Expired
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	United States	62/431,279	12/07/2016		Expired

Name of Entity	Owner(s) (Licensor(s))	Title	Jurisdiction	Application No.	Filing Date	Patent No. (Grant Date)	Status
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	United States	62/570,451	10/10/2017		Expired
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	United States	62/582,814	11/07/2017		Expired
UroGen Pharma Ltd	Agennus Inc.; Ludwig Institute for Cancer Research Ltd; and Memorial Sloan Kettering Cancer Center	ANTIBODIE S AND METHODS OF USE THEREOF	United States	62/586,605	11/15/2017		Expired

PATENT

REEL: 059302 FRAME: 0523

RECORDED: 03/18/2022